3D-bioengineered model of human skeletal muscle tissue with phenotypic features of aging for drug testing purposes
Source abstract
Abstract
Abstract Three-dimensional engineering of skeletal muscle is becoming increasingly relevant for tissue engineering, disease modeling and bio-hybrid robotics, where flexible, versatile and multidisciplinary approaches for the evaluation of tissue differentiation, functionality and force measurement are required. This works presents a 3D-printed platform of bioengineered human skeletal muscle which can efficiently model the three-dimensional structure of native tissue, while providing information about force generation and contraction profiles. Proper differentiation and maturation of myocytes is demonstrated by the expression of key myo-proteins using immunocytochemistry and analyzed by confocal microscopy, and the functionality assessed via electrical stimulation and analysis of contraction kinetics. To validate the flexibility of this platform for complex tissue modeling, the bioengineered muscle is treated with tumor necrosis factor α to mimic the conditions of aging, which is supported by morphological and functional changes. Moreover, as a proof of concept, the effects of Argireline® Amplified peptide, a cosmetic ingredient that causes muscle relaxation, are evaluated in both healthy and aged tissue models. Therefore, the results demonstrate that this 3D-bioengineered human muscle platform could be used to assess morphological and functional changes in the aging process of muscular tissue with potential applications in biomedicine, cosmetics and bio-hybrid robotics.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Muscle Physiology and Disorders · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. 25th anniversary article: engineering hydrogels for biofabrication10.1002/adma.201302042 ↗
2. Force modulation and adaptability of 3D-bioprinted biological actuators based on skeletal muscle tissue10.1002/admt.201800631 ↗
3. Composite biomaterials as long-lasting scaffolds for 3D bioprinting of highly aligned muscle tissue10.1002/mabi.201800167 ↗
4. Muscle-on-a-chip with an on-site multiplexed biosensing system for in situ monitoring of secreted IL-6 and TNF-α10.1039/C9LC00285E ↗
5. Miniaturized soft bio-hybrid robotics: a step forward into healthcare applications10.1039/C6LC90088G ↗
6. Three-dimensionally printed biological machines powered by skeletal muscle10.1073/pnas.1401577111 ↗
7. Simulation and fabrication of stronger, larger, and faster walking biohybrid machines10.1002/adfm.201801145 ↗
8. Biohybrid robot powered by an antagonistic pair of skeletal muscle tissues10.1126/scirobotics.aat4440 ↗
9. Mestre · 2018 · vol · 31610.1007/978-3-319-95972-6_33 ↗
10. Mestre · 2019 · vol · 20510.1007/978-3-030-24741-6_18 ↗
11. Formation and optogenetic control of engineered 3D skeletal muscle bioactuators10.1039/c2lc40338b ↗
12. A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues10.1089/ten.tea.2011.0341 ↗
13. Drug-screening platform based on the contractility of tissue-engineered muscle10.1002/mus.20931 ↗
14. A modular approach to the design, fabrication, and characterization of muscle-powered biological machines10.1038/nprot.2016.185 ↗
15. Mechanical stimulation improves tissue-engineered human skeletal muscle10.1152/ajpcell.00595.2001 ↗
16. Cyclic mechanical preconditioning improves engineered muscle contraction10.1089/tea.2007.0104 ↗
17. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs10.7554/eLife.04885 ↗
18. TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle10.1096/fj.04-2364com ↗
19. TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism10.1186/2044-5040-2-2 ↗
20. Induction of MuRF1 is essential for TNF-α-induced loss of muscle function in mice10.1016/j.jmb.2008.08.087 ↗
21. Myeloid cell-derived tumor necrosis factor-alpha promotes sarcopenia and regulates muscle cell fusion with aging muscle fibers10.1111/acel.12828 ↗
22. Inflammatory cytokines tumour necrosis factor-α and interleukin-8 enhance airway smooth muscle contraction by increasing L-type Ca2+ channel expression10.1111/1440-1681.13030 ↗
23. Effect of tumor necrosis factor α on electrically induced calcium transients elicited in C2C12 skeletal myotubes10.1002/mus.20635 ↗
24. Tumor necrosis factor-α inhibits myogenesis through redox-dependent and -independent pathways10.1152/ajpcell.00418.2001 ↗
25. Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/MTOR/FoxO1 signaling in C2C12 myotubes10.1016/j.intimp.2014.02.002 ↗
26. The role of tumor necrosis factor-alpha (TNF-α in skeletal muscle regeneration: studies in TNF-α(-/-) and TNF-α(-/-)/LT-α(-/-) mice10.1177/002215540104900807 ↗
27. Botulinum neurotoxins: biology, pharmacology, and toxicology10.1124/pr.116.012658 ↗
28. Autophagic degradation contributes to muscle wasting in cancer cachexia10.1016/j.ajpath.2012.12.023 ↗
29. Role of adipose tissue in facial aging10.2147/CIA.S151599 ↗
30. Analysis of facial soft tissue changes with aging and their effects on facial morphology: a forensic perspective10.1016/j.ejfs.2014.07.006 ↗
31. Cosmetic use of botulinum toxin type A in the elderly10.2147/ciia.2007.2.1.81 ↗
32. Comparison and overview of currently available neurotoxins
33. Techniques to evaluate elderly human muscle10.1093/gerona/53A.3.B204 ↗
34. Age- and gender-related changes in contractile properties of non-atrophied EDL muscle10.1371/journal.pone.0012345 ↗
35. Age-related functional changes and susceptibility to eccentric contraction-induced damage in skeletal muscle cell10.1016/j.imr.2016.05.004 ↗
36. Structural aging: the facial recurve concept10.1007/s00266-006-0024-9 ↗
37. Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis10.1046/j.1471-4159.2003.02133.x ↗
38. A synthetic hexapeptide (Argireline) with antiwrinkle activity10.1046/j.1467-2494.2002.00153.x ↗
39. Matrix metalloproteinases and skeletal muscle: a brief review10.1002/mus.10529 ↗
40. Control of collagen gel mechanical properties through manipulation of gelation conditions near the sol–gel transition10.1039/C7SM01933E ↗
41. Investigating the life expectancy and proteolytic degradation of engineered skeletal muscle biological machines10.1038/s41598-017-03723-8 ↗
42. Muscle changes in aging: understanding sarcopenia10.1177/1941738113502296 ↗
43. The age-related loss of skeletal muscle mass and function: measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans10.1016/j.arr.2018.07.005 ↗
44. The role of extracellular matrix composition in structure and function of bioengineered skeletal muscle10.1016/j.biomaterials.2011.01.062 ↗